GlobeNewswire·Nov 6, 2026, 12:00 PM ET

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

Perspective Therapeutics announced interim monotherapy results for its investigational targeted alpha therapy [212 Pb]lapemelanotide zapixetar (VMT01) from a Phase 1/2a trial presented at the SITC 41st Annual Meeting in November 2026.
Data covered 20 patients across three monotherapy dose cohorts with cumulative doses up to 4.5 mCi, 9 mCi, & 15 mCi as of the September 18, 2026 data cut-off.
At the focus dose of 3.0 mCi, the disease control rate was 75% with one confirmed responder remaining in partial response & on study for approximately 40 weeks post-treatment.
No dose-limiting toxicities, treatment-related serious adverse events, or adverse event-related discontinuations were reported across the 20 patients.
Grade 3 or higher treatment-emergent adverse events occurred in 25% of patients but were not considered treatment-related.
The Company plans to continue evaluating & optimizing the dose of lapemelanotide to inform future clinical development.
VMT01 is designed to target MC1R-expressing metastatic melanoma tumors using the alpha-generating isotope 212 Pb as part of a theranostic approach.
The trial is an open-label dose escalation & expansion study (NCT05655312) for patients with histologically confirmed melanoma & MC1R-positive imaging scans.